Department of Clinical Infectious Diseases, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Department of Microbiology, Toyama University Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan.
Front Immunol. 2024 Apr 17;15:1377014. doi: 10.3389/fimmu.2024.1377014. eCollection 2024.
Acute immune responses to coronavirus disease 2019 (COVID-19) are influenced by variants, vaccination, and clinical severity. Thus, the outcome of these responses may differ between vaccinated and unvaccinated patients and those with and without COVID-19-related pneumonia. In this study, these differences during infection with the Omicron variant were investigated.
A total of 67 patients (including 47 vaccinated and 20 unvaccinated patients) who were hospitalized within 5 days after COVID-19 symptom onset were enrolled in this prospective observational study. Serum neutralizing activity was evaluated using a pseudotyped virus assay and serum cytokines and chemokines were measured. Circulating follicular helper T cell (cTfh) frequencies were evaluated using flow cytometry.
Twenty-five patients developed COVID-19 pneumonia on hospitalization. Although the neutralizing activities against wild-type and Delta variants were higher in the vaccinated group, those against the Omicron variant as well as the frequency of developing pneumonia were comparable between the vaccinated and unvaccinated groups. IL-6 and CXCL10 levels were higher in patients with pneumonia than in those without it, regardless of their vaccination status. Neutralizing activity against the Omicron variant were higher in vaccinated patients with pneumonia than in those without it. Moreover, a distinctive correlation between neutralizing activity against Omicron, IL-6 levels, and cTfh proportions was observed only in vaccinated patients.
The present study demonstrates the existence of a characteristic relationship between neutralizing activity against Omicron, IL-6 levels, and cTfh proportions in Omicron breakthrough infection.
新型冠状病毒病 2019(COVID-19)的急性免疫反应受变体、疫苗接种和临床严重程度的影响。因此,这些反应的结果可能在接种和未接种疫苗的患者以及有和没有 COVID-19 相关肺炎的患者之间有所不同。在这项研究中,研究了奥密克戎变体感染期间的这些差异。
这项前瞻性观察性研究共纳入了 67 名在 COVID-19 症状出现后 5 天内住院的患者(包括 47 名接种疫苗和 20 名未接种疫苗的患者)。使用假型病毒测定法评估血清中和活性,并用流式细胞术评估循环滤泡辅助 T 细胞(cTfh)的频率。
25 名患者在住院期间发生 COVID-19 肺炎。尽管接种组对野生型和 Delta 变体的中和活性较高,但接种组和未接种组对奥密克戎变体的中和活性以及发生肺炎的频率相当。无论接种状态如何,肺炎患者的 IL-6 和 CXCL10 水平均高于无肺炎患者。接种组有肺炎的患者对奥密克戎变体的中和活性高于无肺炎的患者。此外,仅在接种组中观察到奥密克戎变体的中和活性、IL-6 水平和 cTfh 比例之间存在独特的相关性。
本研究表明,奥密克戎突破感染中存在奥密克戎变体的中和活性、IL-6 水平和 cTfh 比例之间的特征性关系。